Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ono Aims Higher with Aggressive Open Innovation in Drug Discovery
April 19, 2023
-
BUSINESS Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
-
REGULATORY LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
-
REGULATORY Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
-
ORGANIZATION Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
April 17, 2023
-
ORGANIZATION Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
April 17, 2023
-
BUSINESS AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
April 14, 2023
-
BUSINESS Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers
April 13, 2023
-
REGULATORY Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
-
BUSINESS Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
-
BUSINESS Amgen Eyes Simultaneous Filing in Japan, US, EU for 3 Key Drivers, including Next-Gen BiTE Drug: R&D Chief
April 11, 2023
-
BUSINESS Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
April 10, 2023
-
REGULATORY 9-Valent HPV Vaccine Program Poses Opportunity to Boost Inoculation Rate: LDP Lawmaker
April 7, 2023
-
BUSINESS MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
April 6, 2023
-
REGULATORY Expert Panel Mixed on Macroeconomic Indexing of Drug Cost; Govt Urged to Quit Targeting Pharma for Savings
April 5, 2023
-
BUSINESS 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
-
COMMENTARY Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
BUSINESS Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
-
ACADEMIA Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
-
REGULATORY Audit Questions Rationale for Order of 882 Million COVID Vaccine Doses
March 30, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…